SEQENS

Change in SEQENS’ Shareholding Structure – SEQENS Is Now Stronger, More Focused and Positioned as One of the World's Leading Players in Pharmaceutical Solutions and Specialty Ingredients

Retrieved on: 
Friday, December 17, 2021
Other Manufacturing, Finance, Chemicals, Plastics, Professional Services, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, Organization, Lipid, API, Mineral, Growth, Biocatalysis, Industry, Plant, Culture, Social Security Government Pension Offset, Social, Wavelength, Research, Sodium bicarbonate, Investment, Program, Financial services, Fine chemical, Biophysical environment, Bpifrance, SEQENS, SK CAPITAL, Bpifrance, SEQENS, SK CAPITAL, BPIFRANCE

Concurrent with this investment, SEQENS has combined with Wavelength Pharmaceuticals, an API development and manufacturing company and an existing SK Capital portfolio company.

Key Points: 
  • Concurrent with this investment, SEQENS has combined with Wavelength Pharmaceuticals, an API development and manufacturing company and an existing SK Capital portfolio company.
  • The company has a large product portfolio of more than 200 active pharmaceutical ingredients, 500 pharmaceutical intermediates, as well as key specialty ingredients and chemicals.
  • We are very excited to have the opportunity to support SEQENS with our deep experience and relationships in the pharmaceutical and specialty ingredients markets.
  • SEQENS is a French industrial success story and a leading force in the pharmaceutical and specialty ingredient industries, with a strong footprint in France.

Virpax Announces MMS019 Manufacturing and Supply Agreement

Retrieved on: 
Thursday, August 26, 2021
Science, Other Science, Biotechnology, Pharmaceutical, Surgery, Health, Infectious Diseases, Other Health, Industry, Company, Nanoparticle, Bupivacaine, Securities Exchange Act of 1934, CNS, Pain, Drug Quality and Security Act, Cancer, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, Nature, Nanotechnology, Research, Private Securities Litigation Reform Act, Cosmetics, Social responsibility, Post-traumatic stress disorder, Electronics, Securities Act of 1933, Osteoarthritis, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NASDAQ, Pain management, MET, Morphine, Food, Chronic pain, CEO, Culture, FDA, Brain, COVID-19, PTSD, Spray drying, Security (finance), Pharmaceutical industry, Fine chemical, Vaccine, Risk management, MMS019, Seqens, Virpax Pharmaceuticals, MMS019, SEQENS, VIRPAX PHARMACEUTICALS

The agreement with Seqens provides for both the supply material for Virpaxs clinical studies as well as the long-term commercial supply of MMS019.

Key Points: 
  • The agreement with Seqens provides for both the supply material for Virpaxs clinical studies as well as the long-term commercial supply of MMS019.
  • Seqens will conduct process development and validation of additional large scale commercial quantities of MMS019 at its facilities in Devens and Newburyport, Massachusetts.
  • Establishing a collaboration with a strong partner capable of supplying clinical and commercial scale quantities of MMS019 is another important advancement in our MMS019 product development strategy.
  • Seqens has a demonstrated expertise in developing and manufacturing highly-complex molecules for large scale production, said Anthony Mack, Chairman and CEO of Virpax.